Evidence map›Paper›PMID 35111558›Full record

ArticleFujita medical journal2021

Vitamin K2 supplementation and the progression of abdominal aortic calcification in dialysis patients.

Shoya Oyama, Naoki Okamoto, Shigehisa Koide, Hiroki Hayashi, Shigeru Nakai, Kazuo Takahashi, Daijo Inaguma, Midori Hasegawa, Hiroshi Toyama, Satoshi Sugiyama and 2 more

Open access · greenAbstract read
In one paragraph

Article in Fujita medical journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Shoya OyamaDepartment of Nephrology, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan.
Naoki OkamotoDepartment of Nephrology, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan.
Shigehisa KoideDepartment of Nephrology, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan.
Hiroki HayashiDepartment of Nephrology, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan.
Shigeru NakaiFaculty of Clinical Engineering, Fujita Health University, School of Medical Sciences, Toyoake, Aichi, Japan.
Kazuo TakahashiDepartment of Biomedical Molecular Sciences, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan.
Daijo InagumaDepartment of Nephrology, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan.
Midori HasegawaDepartment of Nephrology, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan.
Hiroshi ToyamaDepartment of Radiology, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan.
Satoshi SugiyamaDepartment of Radiology, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan.
Yukio YuzawaDepartment of Nephrology, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan.
Naotake TsuboiDepartment of Nephrology, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan.
Fujita Health University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesVascular calcification is common in patients with advanced chronic kidney disease (CKD) and contributes to cardiovascular disease. Accumulating evidence indicates that CKD patients often acquire subclinical vitamin K deficiency, which is associated with vascular calcification.

methodsThis prospective, randomized, parallel group, multicenter trial (UMINID000011490) will include 200 dialysis patients in an open-label, two-arm design. After baseline computed tomography of the abdominal aorta, patients will be randomized to two groups that will either (1) continue receiving standard care or (2) receive additional oral supplementation with menatetrenone (45 mg/day). The treatment duration will be 24 months, and the computed tomography scan will be repeated after 12 and 24 months. The primary endpoint is the progression of abdominal aortic calcification, which is calculated as absolute changes based on the Agatston score. The secondary endpoints are the decrease in bone mineral density (measured by dual-energy X-ray absorptiometry), the biomarkers associated with vitamin K, vitamin K intake (evaluated by the food frequency questionnaire), and the biomarkers associated with vascular calcification.

conclusionsThis study aims to confirm whether vitamin K has inhibitory effects on calcification that can be clinically determined.

trial registrationUMINID000011490.

Indexed as

Agatston scoreAortic abdominal calcificationDialysisRandomized control trialVitamin K

Identifiers

PMID35111558
PMCPMC8761817
OpenAlexW3112703474

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.